{"info":{"title":"Theaslangroupllc","version":"1.0.0"},"openapi":"3.1.0","paths":{"/api/clinical/approval-outlook":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"250000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Approval Outlook","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents."}},"/api/clinical/deal-signal":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"350000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Deal Signal","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents."}},"/api/clinical/disease-landscape":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"350000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Disease Landscape","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents."}},"/api/clinical/drug-check":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"100000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Drug Check","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"What is this medication? Plain-language explainer for any prescription or OTC drug from its FDA-approved label — what it treats, how to take it, boxed warnings, who should not take it, common and serious side effects, pregnancy notes. For patient, caregiver, pharmacy, and health-assistant agents."}},"/api/clinical/global-trials":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"150000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Global Trials","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents."}},"/api/clinical/interaction-check":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"150000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Interaction Check","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Can these medications be taken together? Cross-references the FDA-approved drug-interaction and contraindication sections for 2+ drugs and flags possible interactions in plain language, with severity and what-to-do. For patient, caregiver, pharmacy, and health-assistant agents managing a medication list."}},"/api/clinical/mechanism-map":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"200000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Mechanism Map","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents."}},"/api/clinical/patient-finder":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"100000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Patient Finder","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Recruiting clinical trial finder for a disease or diagnosis — actively recruiting trials with plain-language summaries, eligibility (who can/cannot join), country filter, contacts and how to apply, across 400,000+ ClinicalTrials.gov studies worldwide. For patient-advocacy and provider agents."}},"/api/clinical/recall-check":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"100000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Recall Check","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Is my medication recalled? Checks the FDA enforcement databases (drug AND food — infant formula and supplements are filed under food) for active and past recalls, explains the recall class (I/II/III) in plain language, and lays out what to do. For patient, caregiver, pharmacy, and health-assistant agents."}},"/api/clinical/sponsor-intel":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"200000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Sponsor Intel","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents."}},"/api/clinical/trial-brief":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"100000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Trial Brief","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents."}},"/api/clinical/trial-check":{"get":{"responses":{"200":{"description":"Successful response"},"402":{"description":"Payment Required"}},"x-payment-info":{"offers":[{"amount":"20000","currency":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","description":"Theaslangroupllc: Clinical Trial Check","intent":"charge","method":"evm","recipient":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"}]},"summary":"ClinicalTrials.gov lookup, deterministic. Answers \"what is the status of NCT02142738\", \"recruiting phase-3 melanoma trials\", \"Pfizer trial pipeline\". Single trial by NCT id (status, phase, sponsor, enrollment, dates, countries) or search by condition/sponsor with phase and status filters. Typed records straight off the official v2 API — no LLM, no key, public domain."}}},"x-service-info":{"description":"Theaslangroupllc is an x402-native service at https://clinicalintelpulse.theaslangroupllc.com, indexed from the x402 Bazaar (Coinbase's public discovery directory). It charges callers itself in USDC on Base and is paid directly at its own wallet; Monex Protocol passes your request and payment headers through untouched. 12 endpoints listed."}}